Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of the qualifying criteria for (a) Ozempic and (b) Wegovy.

The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE evaluates medicines in accordance with their marketing authorisations, including any criteria set out in the summary of product characteristics, granted by the Medicines and Healthcare products Regulatory Agency. The National Health Service in England is legally required to fund medicines and treatments recommended by NICE under its technology appraisal and highly specialised technologies programmes. NICE develops its recommendations in line with its established methods and processes which include a careful consideration of the evidence and engagement with stakeholders.

NICE has published guidance that recommends the medicine semaglutide subject to specified clinical criteria for use in the treatment of type 2 diabetes, for which it is marketed as Ozempic, and for use in weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity in adults, for which it is marketed as Wegovy. NICE is currently planning a review of its guidance on the use of semaglutide in the treatment of weight loss and, subject to licensing, developing recommendations on its use for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity.